Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idacio
- Development stage
- Approved
- Lead developer
- Fresenius Kabi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Idacio is a biosimilar of adalimumab, a recombinant human monoclonal antibody that targets and binds to tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine. By inhibiting TNF-α, Idacio reduces inflammation and modulates immune responses in autoimmune diseases. It is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. Idacio is administered as a subcutaneous injection and can be used alone or in combination with other disease-modifying antirheumatic drugs (DMARDs). It was developed as a biosimilar to Humira (adalimumab) and demonstrates similar efficacy and safety profiles[1][2][3][4][5][6].
- Brand names
- Idacio
- Other names
- adalimumab-aacf
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on idacio.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idacio.